Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL6154150 | 0.98 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL1255344 | 0.98 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL9389700 | 0.85 | CA12 (0.35) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL1255349 | 0.83 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL525285 | 0.78 | LMNA (0.50) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL4598410 | 0.77 | CA12 (0.38) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL27705092 | 0.76 | USP2 (0.38) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL3691589 | 0.75 | TSHR (0.41) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL130983 | 0.74 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL30708584 | 0.73 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856748-B1 | METAL-ORGANIC FRAMEWORK PHASE AND CRYSTALLITE SHAPE CONTROL | UNIV CALIFORNIA (US) | 2024-03-06 | — | — | EP | claimed |
| US-10786602-B2 | Method for treating surface of implant | OSSTEMIMPLANT CO., LTD. (KR) | 2020-09-29 | — | — | US | claimed |
| WO-2019178587-A1 | PURIFICATION OF TARGET MOLECULES | BIO-RAD LABORATORIES, INC. (US) | 2019-09-19 | — | — | WO | claimed |
| US-10301669-B2 | Detection of genetic sequences using PNA probes and Isotachophoresis | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-05-28 | — | — | US | claimed |
| WO-2018199698-A1 | COMPOSITION COMPRISING FIBROUS ACELLULAR DERMAL MATRIX AND BIOCOMPATIBLE POLYMER, AND METHOD FOR PRODUCING SAME | (주)시지바이오 | 2018-11-01 | — | — | WO | claimed |
| WO-2017074093-A1 | WOUND DRESSING MATERIAL COMPRISING FIBRILLATED ACELLULAR DERMIS MATRIX AND BIODEGRADABLE POLYMER, AND PREPARATION METHOD THEREFOR | 주식회사 시지바이오 | 2017-05-04 | — | — | WO | claimed |
| EP-2992908-A1 | METHOD FOR TREATING SURFACE OF IMPLANT | Osstemimplant Co., Ltd. (KR) | 2016-03-09 | — | — | EP | claimed |
| US-20160058920-A1 | Method for Treating Surface of Implant | OSSTEMIMPLANT CO., LTD. (KR) | 2016-03-03 | — | — | US | claimed |
| US-20150283245-A1 | STABILIZER FOR HYALURONIDASE AND LIQUID FORMULATION COMPRISING HYALURONIDASE | BMI KOREA CO., LTD (KR) | 2015-10-08 | — | — | US | claimed |
| EP-2914246-A1 | STABILIZER FOR HYALURONIDASE AND LIQUID FORMULATION COMPRISING HYALURONIDASE | BMI Korea Co. Ltd (KR) | 2015-09-09 | — | — | EP | claimed |
| WO-2014069757-A1 | STABILIZER FOR HYALURONIDASE AND LIQUID FORMULATION COMPRISING HYALURONIDASE | BMI KOREA CO., LTD (KR) | 2014-05-08 | — | — | WO | claimed |
| WO-2014030975-A1 | METHOD FOR MANUFACTURING CARBON NANOTUBE-BASED ANTI-CANCER AGENT SUPPRESSING CANCER CELL RESISTANCE | 경상대학교 산학협력단 (KR) | 2014-02-27 | — | — | WO | claimed |
| US-20120149868-A1 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS | NOVO NORDISK A/S (DK) | 2012-06-14 | — | — | US | claimed |
| WO-2011105663-A1 | METHOD FOR PRODUCING AN ACELLULAR DERMAL MATRIX, AND ACELLULAR DERMAL MATRIX PRODUCED BY SAME | (주)시지바이오 (KR) | 2011-09-01 | — | — | WO | claimed |
| US-6733586-B2 | High throughput non-photochemical laser induced nucleation | ILLINOIS INSTITUTE OF TECHNOLOGY | 2004-05-11 | — | — | US | claimed |
| WO-2004016834-A1 | HIGH THROUGHPUT NON-PHOTOCHEMICAL LASER INDUCED NUCLEATION | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2004-02-26 | — | — | WO | claimed |
| US-6596077-B2 | Controlled nucleation of protein crystals | ILLINOIS INSTITUTE OF TECHNOLOGY | 2003-07-22 | — | — | US | claimed |
| US-20030101926-A1 | High throughput non-photochemical laser induced nucleation | INTELLECTUAL VENTURES HOLDING 19, LLC | 2003-06-05 | — | — | US | claimed |
| WO-2003012177-A1 | CONTROLLED NUCLEATION OF PROTEIN CRYSTALS | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2003-02-13 | — | — | WO | claimed |
| US-20030024470-A1 | Controlled nucleation of protein crystals | INTELLECTUAL VENTURES HOLDING 19, LLC | 2003-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149868-A1 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS | VIP, IAPP, NGLY1 | ALDH1A1 4607/4885LMNA 2989/4885MAPT 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.